18F-FDG PET imaging in posttherapy monitoring of cervical cancers: From diagnosis to prognosis

Journal of Nuclear Medicine

Volumn 45, Issue 10, 2004, Pages 1602-1604

  Belhocine, Tarik Z ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC PROCEDURE; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SHORT SURVEY; UTERINE CERVIX CANCER; CLINICAL TRIAL; FEMALE; METHODOLOGY; NOTE; PROGNOSIS; SCINTISCANNING; TREATMENT OUTCOME; UTERINE CERVIX TUMOR;

CLINICAL TRIALS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS;

EID: 16544366426     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (27)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001;94:153-156.
2. Drain PK, Holmes KK, Hughes JP, Koutsky LA. Determinants of cervical cancer rates in developing countries. Int J Cancer. 2002;100:199-205.
3. Benedet JL, Bender H, Jones H 3rd, Ngan HY, Pecorelli S. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers: FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet. 2000;70:209-262.
4. Chi DS, Lanciano RM, Kudelka AP. Cancer management: a multidisciplanry approach. Cervical Cancer. 5th ed. New York, NY: PRR, Inc.; 2001.
5. Olaitan A, Murdoch J, Anderson R, James J, Graham J, Barley V. A critical evaluation of current protocols for the follow-up of women treated for gynecological malignancies: a pilot study. Int J Gynecol Cancer. 2001;11:349-353.
6. Sugawara Y, Eisbruch A, Kosuda S, Recker BE, Kison PV, Wahl RL. Evaluation of FDG PET in patients with cervical cancer. J Nucl Med. 1999;40:1125-1131.
7. Grigsby PW, Dehdashti F, Siegel BA. FDG-PET evaluation of carcinoma of the cervix. Clin Positron Imaging. 1999;2:102-109.
8. 18F-FDG-PET) in the diagnosis of recurrence and lymph node metastasis of cervical cancer. Oncol Rep. 2000;7:1261-1264.
9. Kerr IG, Manji MF, Powe J, Bakheet S, Al Suhaibani H, Subhi J. Positron emission tomography for the evaluation of metastases in patients with carcinoma of the cervix: a retrospective review. Gynecol Oncol. 2001;81:477-480.
10. Park DH, Kim KH, Park SY, Lee BH, Choi CW, Chin SY. Diagnosis of recurrent uterine cervical cancer: computed tomography versus positron emission tomography. Korean J Radiol. 2000;1:51-55.
11. 18F-fluoro-2-deoxyglucose positron emission tomography in the evaluation of recurrent cervical cancer. Anticancer Res. 2001;21:2957-2961.
12. Nakamoto Y, Eisbruch A, Achtyes ED, et al. Prognostic value of positron emission tomography using F-18-fluorodeoxyglucose in patients with cervical cancer undergoing radiotherapy. Gynecol Oncol. 2002;84:289-295.
13. 18FDG PET imaging in the management of cervical cancer. Gynecol Oncol. 2002;87:90-97.
14. Havrilesky LJ, Wong TZ, Secord AA, Berchuck A, Clarke-Pearson DL, Jones EJ. The role of PET scanning in the detection of recurrent cervical cancer. Gynecol Oncol. 2003;90:186-190.
15. 18F-FDG PET in patients with cervical cancer. J Nucl Med. 2003;44:347-352.
16. 18F]-fluoro-2-deoxy-D-glucose positron emission tomography. Cancer. 2004;100:544-552.
17. 18F-FDG PET imaging in post-therapy of uterine cancers: clinical evidence and a research proposal. Int J Gynecol Cancer. 2003;13:228-233.
18. 18F]fluorodeoxyglucose positron emission tomography in carcinoma of the cervix: response and outcome. J Clin Oncol. 2004;22:2167-2171.
19. Fiorica JV. Update on the treatment of cervical and uterine carcinoma: focus on topotecan. Oncologist. 2002;7(suppl 5):36-45.
20. Grigsby PW, Siegel BA, Dehdashti F, Mutch DG. Posttherapy surveillance monitoring of cervical cancer by FDG-PET. Int J Radiat Oncol Biol Phys. 2003;55:907-913.
21. Laking GR, Price PM. On the development of rational standards for nuclear response evaluation. Q J Nucl Med. 2003;47:3-7.
22. 18F-FDG PET for recurrent cervical cancer. J Nucl Med. 2004;45:1632-1639.
23. Bodurka-Bevers D, Morris M, Eifel PJ, et al. Posttherapy surveillance of women with cervical cancer: an outcomes analysis. Gynecol Oncol. 2000;78:187-193.
24. Maiman M. The clinical application of serum squamous cell carcinoma antigen level monitoring in invasive cervical carcinoma. Gynecol Oncol. 2002;84:4-6.
25. Kluetz PG, Meltzer CC, Villemagne VL, et al. Combined PET/CT imaging in oncology: impact on patient management. Clin Positron Imaging. 2000;3:223-230.
26. Wahl RL. Why nearly all PET of abdominal and pelvic cancers will be performed as PET/CT. J Nucl Med. 2004;45(suppl 1):82S-95S.
27. Kim EE. Whole-body positron emission tomography and positron emission tomography/computed tomography in gynecologic oncology. Int J Gynecol Cancer. 2004;14:12-22.